Unfortunately, the original version of this article [1] contained an error. Table Two (Table 1 here) was included incorrectly. The correct Table Two (Table 1 here) can be found below:
Table 1.
ACTH Test 1 and 2 classified according to groups of Δ cortisol <, ≥ 250 nmol/L
| Test 1 Δ<250 nmol/L | Test 1 Δ≥250 nmol/L | Test 2 Δ<250 nmol/L | Test 2 Δ≥250 nmol/L | P Δ cortisol, time, interaction | |
|---|---|---|---|---|---|
| n=17 | n=42 | n=14 | n=45 | ||
| ACTH, pmol/L | 3.1 (1.1–18.0) | 1.5 (1.1–15.0) | 6.0 (1.1–14.0) | 3.8 (1.0–8.9) | 0.001, 0.025, 0.72 |
| Baseline cortisol, nmol/L | 470 (200–1355) | 430 (75–2670) | 655 (335–1890) | 495 (35–2670) | 0.021, 0.12, 0.30 |
| Baseline cortisol/ACTH, nmol/pmol | 148 (36–250) | 238 (14–2054) | 109 (48–1718) | 126 (35–2054) | 0.029, 0.16, 0.14 |
| Baseline free cortisol, nmol/L | 77 (63–357) (n=9) | 86 (38–256) (n=14) | 154 (114–252) (n=6) | 75 (4–151) (n=20) | 0.001, 0.91, 0.19 |
| Baseline free cortisol/ACTH, nmol/pmol | 22 (9–38) | 39 (16–89) | 26 (11–43) | 17 (4–35) | 0.042, 0.10, <0.001 |
| Δ cortisol, nmol/L | 140 (−50–245) | 388 (260–4015) | 177 (−80–230) | 425 (255–965) | n.a., 0.45, 0.093 |
| Δ free cortisol, nmol/L | 59 (−71–124) | 151 (74–678) | 40 (−34–99) | 133 (32–233) | <0.001, 0.15, 0.16 |
| CBG, mg/L | 23 (6–43) | 29 (13–63) | 39 (4–60) | 41 (21–65) | 0.060, <0.001, 0.90 |
| Albumin, g/L | 13 (6–32) | 17 (6–24) | 16 (12–28) | 20 (8–32) | 0.25, <0.001, 0.89 |
| Days from admission - test | 1 (0–50) | 3 (0–44) | 25 (9–49) | 20 (9–83) | 0.57*, 0.15* |
| Days between tests | n.a. | n.a. | 18 (8–34) | 16 (8–43) | 0.41* |
| Days after stop hydrocortisone | n.a. | n.a. | 7 (5–12) | 7 (5–14) | 0.75* |
Median (range); ACTH: adrenocorticotropic hormone, CBG: cortisol binding globulin. *Mann–Whitney U test, otherwise generalized estimating equations; n.a.: not applicable
Footnotes
The online version of the original article can be found under doi:10.1186/s13054-014-0721-8.
Reference
- 1.de Jong MF, Molenaar N, Beishuizen A, Groeneveld AB. Diminished adrenal sensitivity to endogenous and exogenous adrenocorticotropic hormone in critical illness: a prospective cohort study. Critical Care. 2015;19:1. doi: 10.1186/s13054-014-0721-8. [DOI] [PMC free article] [PubMed] [Google Scholar]